William Rosenberg

William Rosenberg

Auto-generated profile, based on publicly available information

William Rosenberg

Division of Medicine, Institute for Liver and Digestive Health, University College London

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 1996 in BMJ
Verified
Journal Article
Closed access
DSDavid L Sackett
David L Sackett
WRWilliam M C Rosenberg
William M C Rosenberg
JGJ A Muir Gray
J A Muir Gray
RHR Brian Haynes
R Brian Haynes
WRW Scott Richardson
W Scott Richardson

1 March 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SBSarah Blach
Sarah Blach
SZStefan Zeuzem
Stefan Zeuzem
MMMichael Manns
Michael Manns
IAIbrahim Altraif
Ibrahim Altraif
ADAnn-Sofi Duberg
Ann-Sofi Duberg
HRHomie Razavi
Homie Razavi

6 August 2004 in Science
Verified
Journal Article
Closed access
SKSalim I Khakoo
Salim I Khakoo
CTChloe L. Thio
Chloe L. Thio
MMMaureen P. Martin
Maureen P. Martin
CBCollin R. Brooks
Collin R. Brooks
XGXiaojiang Gao
Xiaojiang Gao
MCMary Carrington
Mary Carrington
Natural killer (NK) cells provide a central defense against viral infection by using inhibitory and activation receptors for major histocompatibility complex class I molecules as a means of controlling their activity. We show that genes encoding the inhibitory NK cell receptor KIR2DL3 and its human leukocyte antigen C group1 (HLA-C1) ligand directly influence resolution of hepatitis C virus (HCV) infection. This effect was observed in Caucasians and African Americans with expected low infectious doses of HCV but not in those with high-dose exposure, in whom the innate immune response is likely overwhelmed. The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV.

1 December 2004 in Gastroenterology
Verified
Journal Article
Closed access
WRWilliam M.C. Rosenberg
William M.C. Rosenberg
MVMichael Voelker
Michael Voelker
TRThiel R
Thiel R
MBMichael Becka
Michael Becka
BABurt A
Burt A
TRTania Roskams
Tania Roskams

29 April 1995 in BMJ
Verified
Journal Article
Closed access
WRWilliam Rosenberg
William Rosenberg
ADAnna Donald
Anna Donald
Doctors within the NHS are confronting major changes at work. While we endeavour to improve the quality of health care, junior doctors' hours have been reduced and the emphasis on continuing medical education has increased. We are confronted by a growing body of information, much of it invalid or irrelevant to clinical practice. This article discusses evidence based medicine, a process of turning clinical problems into questions and then systematically locating, appraising, and using contemporaneous research findings as the basis for clinical decisions. The computerisation of bibliographies and the development of software that permits the rapid location of relevant evidence have made it easier for busy clinicians to make best use of the published literature. Critical appraisal can be used to determine the validity and applicability of the evidence, which is then used to inform clinical decisions. Evidence based medicine can be taught to, and practised by, clinicians at all levels of seniority and can be used to close the gulf between good clinical research and clinical practice. In addition it can help to promote self directed learning and teamwork and produce faster and better doctors. Doctors must cope with a rapidly changing body of relevant evidence and maximise the quality of medical care despite the reduction in junior doctors' working hours and scarce resources. We are deluged with information, and although much of it is either invalid or irrelevant to clinical practice, an increasing amount comes from powerful investigations such as randomised controlled trials. Yet we continue to base our clinical decisions on increasingly out of date primary training or the overinterpretation of experiences with individual patients,1 and even dramatically positive results from rigorous clinical studies remain largely unapplied.2 Doctors need new skills to track down the new types of strong and useful evidence, distinguish it from …

31 December 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GFGraham R. Foster
Graham R. Foster
NANezam Afdhal
Nezam Afdhal
SRStuart K. Roberts
Stuart K. Roberts
NBNorbert Bräu
Norbert Bräu
EGEdward J. Gane
Edward J. Gane
MSMark Sulkowski
Mark Sulkowski
In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV genotype 2 or 3 and those who had not received such treatment, including patients with compensated cirrhosis. In one trial, patients with HCV genotype 2 were randomly assigned in a 1:1 ratio to receive sofosbuvir–velpatasvir, in a once-daily, fixed-dose combination tablet (134 patients), or sofosbuvir plus weight-based ribavirin (132 patients) for 12 weeks. In a second trial, patients with HCV genotype 3 were randomly assigned in a 1:1 ratio to receive sofosbuvir–velpatasvir for 12 weeks (277 patients) or sofosbuvir–ribavirin for 24 weeks (275 patients). The primary end point for the two trials was a sustained virologic response at 12 weeks after the end of therapy. Among patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir–velpatasvir group was 99% (95% confidence interval [CI], 96 to 100), which was superior to the rate of 94% (95% CI, 88 to 97) in the sofosbuvir–ribavirin group (P=0.02). Among patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir–velpatasvir group was 95% (95% CI, 92 to 98), which was superior to the rate of 80% (95% CI, 75 to 85) in the sofosbuvir–ribavirin group (P<0.001). The most common adverse events in the two studies were fatigue, headache, nausea, and insomnia. Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir–velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment with sofosbuvir–ribavirin. (Funded by Gilead Sciences; ASTRAL-2 ClinicalTrials.gov number, NCT02220998; and ASTRAL-3, NCT02201953.)